Vanguard Group Inc. Sells 106,815 Shares of The Clorox Company $CLX

Vanguard Group Inc. lowered its stake in shares of The Clorox Company (NYSE:CLX) by 0.7% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 15,738,681 shares of the company’s stock after selling 106,815 shares during the period. Vanguard Group Inc. owned approximately 0.13% of Clorox worth $1,940,579,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Invesco Ltd. boosted its holdings in Clorox by 138.3% during the second quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock worth $389,648,000 after purchasing an additional 1,883,465 shares during the last quarter. Norges Bank bought a new position in shares of Clorox during the 2nd quarter worth approximately $190,429,000. ProShare Advisors LLC lifted its position in shares of Clorox by 11.7% during the 3rd quarter. ProShare Advisors LLC now owns 1,297,016 shares of the company’s stock worth $159,922,000 after buying an additional 136,135 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its stake in shares of Clorox by 218.4% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock worth $149,983,000 after buying an additional 856,873 shares during the last quarter. Finally, Man Group plc grew its holdings in shares of Clorox by 23.7% in the second quarter. Man Group plc now owns 1,134,263 shares of the company’s stock valued at $136,191,000 after acquiring an additional 217,645 shares in the last quarter. 78.53% of the stock is owned by hedge funds and other institutional investors.

Clorox News Roundup

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox published a new consumer study, “Home Care Redefined,” positioning its portfolio around wellness, convenience and younger consumer priorities — a marketing/innovation push that could support category relevance and pricing power over time. Home Care Redefined
• Neutral Sentiment: Management presented at the Consumer Analyst Group of New York (CAGNY). The slides and prepared remarks provide updated strategic detail for investors (product/portfolio priorities, consumer insights and growth levers). These disclosures are informational and help frame execution risk, but are not a direct catalyst for near‑term earnings revisions. CAGNY Slides CAGNY Transcript
• Negative Sentiment: Zacks Research trimmed multiple near‑term EPS forecasts (several quarters and FY2027 were reduced modestly), and kept a “Hold” stance — a direct negative to sentiment because lower analyst estimates can pressure the stock and reduce upside expectations. (Multiple estimate revisions issued Feb. 17.)
• Negative Sentiment: Wells Fargo moved to a Hold on CLX, reinforcing a cautious view from major street analysts that likely contributed to selling pressure. Wells Fargo Hold

Clorox Stock Performance

NYSE CLX opened at $122.04 on Friday. The firm has a market cap of $14.76 billion, a P/E ratio of 19.94, a price-to-earnings-growth ratio of 0.61 and a beta of 0.59. The company has a quick ratio of 0.48, a current ratio of 0.74 and a debt-to-equity ratio of 71.03. The company’s 50 day moving average is $109.36 and its 200-day moving average is $113.68. The Clorox Company has a 12-month low of $96.66 and a 12-month high of $159.04.

Clorox (NYSE:CLX) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.39 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.04). Clorox had a return on equity of 383.01% and a net margin of 11.17%.The business had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same period last year, the business posted $1.55 earnings per share. The firm’s quarterly revenue was down .8% on a year-over-year basis. Sell-side analysts predict that The Clorox Company will post 7.15 earnings per share for the current year.

Analyst Ratings Changes

CLX has been the topic of a number of recent analyst reports. TD Cowen lifted their price target on Clorox from $108.00 to $111.00 and gave the stock a “hold” rating in a report on Wednesday, February 4th. Barclays reiterated an “underweight” rating and issued a $109.00 target price on shares of Clorox in a research note on Friday, January 16th. Rothschild & Co Redburn set a $117.00 price target on shares of Clorox in a research note on Friday, February 13th. Wells Fargo & Company set a $125.00 price objective on Clorox in a research note on Tuesday. Finally, Evercore reduced their price objective on Clorox from $132.00 to $115.00 and set an “underperform” rating for the company in a report on Wednesday, February 4th. One analyst has rated the stock with a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $118.73.

About Clorox

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.